(HealthDay News) – For individuals with suspected sporadic Creutzfeldt-Jakob disease (sCJD), the cerebrospinal fluid (CSF) 14-3-3 protein assay is a useful diagnostic test, according to research published online Sept 19 in Neurology.
Taim Muayqil, MBBS, from the King Saud University in Saudi Arabia, and colleagues conducted a systematic review of the literature to examine whether CSF 14-3-3 protein accurately identifies CJD in patients with sCJD. Nine class II studies were identified, which included samples from 1,849 patients with suspected sCJD.
The researchers found that CSF 14-3-3 assays were moderately accurate in diagnosing sCJD, with a sensitivity and specificity of 92 and 80%, respectively. The positive likelihood ratio was 4.7 and the negative likelihood ratio was 0.1.
“Standardization of the definition of a positive 14-3-3 result and validation in well-designed cohort studies would be useful,” the authors write. “Further investigation is needed into the utility of CSF biomarkers in subgroups of patients on the basis of demographics, time of presentation, duration of illness, specific etiologies of prion disease, or genetic factors.”
One author disclosed financial ties to the pharmaceutical industry.